Sotera Health Q2 revenue up 6.4% to $294M; Adj EBITDA +9.8% to $151M; raises FY outlook

Sotera Health Co

2025-Q2 EPS reported -$0.02 vs consensus $0.17 ▼ miss (-111.5%)

Q2 net revenues $294M (+6.4% YoY); constant currency +6.0%; net income $8M ($0.03 diluted EPS).
Adjusted EBITDA $151M (+9.8% YoY); Adjusted EPS $0.20 vs $0.19 prior year.
Company raises full-year 2025 outlook: net revenue growth 4.5%-6.0%, Adj EBITDA growth 6.0%-7.5% constant currency.
Net income impacted by $34M pending settlement related to ethylene oxide claims against Sterigenics.
First-half 2025 net revenues $549M (+4.6% YoY); net loss $5M due to settlements totaling $65M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.